These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9932168)

  • 1. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
    Zinzani PL; Magagnoli M; Bendandi M; Orcioni GF; Gherlinzoni F; Albertini P; Pileri SA; Tura S
    Ann Oncol; 1998 Dec; 9(12):1351-3. PubMed ID: 9932168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
    Zinzani PL; Baliva G; Magagnoli M; Bendandi M; Modugno G; Gherlinzoni F; Orcioni GF; Ascani S; Simoni R; Pileri SA; Tura S
    J Clin Oncol; 2000 Jul; 18(13):2603-6. PubMed ID: 10893292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
    Zinzani PL; Venturini F; Stefoni V; Fina M; Pellegrini C; Derenzini E; Gandolfi L; Broccoli A; Argnani L; Quirini F; Pileri S; Baccarani M
    Ann Oncol; 2010 Apr; 21(4):860-863. PubMed ID: 19887465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
    Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Rupoli S; Pileri S; Baccarani M; Zinzani PL
    Cancer; 2005 Dec; 104(11):2437-41. PubMed ID: 16216001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
    Offidani M; Mele A; Corvatta L; Marconi M; Malerba L; Olivieri A; Rupoli S; Alesiani F; Leoni P
    Leuk Lymphoma; 2002 Jun; 43(6):1273-9. PubMed ID: 12152996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
    Friedlander M; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Varette C; Ripoche V; Kayitalire L
    Ann Oncol; 1998 Dec; 9(12):1343-5. PubMed ID: 9932166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
    Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gemcitabine Monotherapy for Advanced Mycosis Fungoides--Two Case Reports and a Literature Review].
    Masuzawa M; Takasu H; Amoh Y
    Gan To Kagaku Ryoho; 2015 Dec; 42(13):2451-5. PubMed ID: 26809303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.
    Zinzani PL; Bendandi M; Stefoni V; Albertini P; Gherlinzoni F; Tani M; Piccaluga PP; Tura S
    Haematologica; 2000 Sep; 85(9):926-9. PubMed ID: 10980630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced breast cancer: a phase II trial with gemcitabine.
    Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
    J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine.
    Awar O; Duvic M
    Oncology; 2007; 73(1-2):130-5. PubMed ID: 18337626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
    Tomao S; Romiti A; Massidda B; Ionta MT; Farris A; Zullo A; Brescia A; Santuari L; Frati L
    Anticancer Res; 2002; 22(4):2361-4. PubMed ID: 12174927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
    Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
    Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
    Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.